[HTML][HTML] Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease
JM Benitez-Del-Castillo… - … & visual science, 2016 - iovs.arvojournals.org
Purpose: To evaluate the efficacy and safety of SYL1001, a short interfering (si) RNA
targeting the transient receptor potential cation channel subfamily V member 1 (TRPV1), for …
targeting the transient receptor potential cation channel subfamily V member 1 (TRPV1), for …
Tivanisiran, a novel siRNA for the treatment of dry eye disease
J Moreno-Montañés, AM Bleau… - Expert Opinion on …, 2018 - Taylor & Francis
Introduction: Dry eye disease (DED) is characterized by an alteration of the tear film with
ocular inflammation and neurosensory abnormalities. The main clinical signs of this …
ocular inflammation and neurosensory abnormalities. The main clinical signs of this …
[HTML][HTML] Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure
J Moreno-Montañés, B Sádaba, V Ruz, A Gómez-Guiu… - Molecular Therapy, 2014 - cell.com
The objective of this study was to evaluate ocular tolerance, safety, and effect on intraocular
pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy …
pressure (IOP) of a topically administered small interfering RNA; SYL040012, on healthy …
RNA therapeutics in ophthalmology-translation to clinical trials
A Gupta, KN Kafetzis, AD Tagalakis… - Experimental eye …, 2021 - Elsevier
The use of RNA interference technology has proven to inhibit the expression of many target
genes involved in the underlying pathogenesis of several diseases affecting various …
genes involved in the underlying pathogenesis of several diseases affecting various …
Small‐interfering RNA s (siRNA s) as a promising tool for ocular therapy
A Guzman‐Aranguez, P Loma… - British journal of …, 2013 - Wiley Online Library
RNA interference (RNAi) can be used to inhibit the expression of specific genes in vitro and
in vivo, thereby providing an extremely useful tool for investigating gene function. Progress …
in vivo, thereby providing an extremely useful tool for investigating gene function. Progress …
[HTML][HTML] A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease
J Tauber, DL Wirta, K Sall, PA Majmudar, D Willen… - Cornea, 2021 - journals.lww.com
Purpose: NOV03 has a unique dual mode of action to address dry eye disease (DED)
associated with meibomian gland dysfunction. SEECASE evaluated the efficacy, safety, and …
associated with meibomian gland dysfunction. SEECASE evaluated the efficacy, safety, and …
Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial
F Amparo, MH Dastjerdi, A Okanobo… - JAMA …, 2013 - jamanetwork.com
Importance The immunopathogenic mechanisms of dry eye disease (DED), one of the most
common ophthalmic conditions, is incompletely understood. Data from this prospective …
common ophthalmic conditions, is incompletely understood. Data from this prospective …
A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye
CP Semba, GL Torkildsen, JD Lonsdale… - American journal of …, 2012 - Elsevier
PURPOSE: To investigate the efficacy and safety of an investigational integrin antagonist
(SAR 1118) ophthalmic solution compared to placebo (vehicle) in subjects with dry eye …
(SAR 1118) ophthalmic solution compared to placebo (vehicle) in subjects with dry eye …
Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: Recent advancements and future perspectives
S Naik, AB Shreya, R Raychaudhuri, A Pandey… - Life Sciences, 2021 - Elsevier
RNA-interference-based mechanisms, especially the use of small interfering RNAs
(siRNAs), have been under investigation for the treatment of several ailments and have …
(siRNAs), have been under investigation for the treatment of several ailments and have …
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
J Tauber, BA Schechter, J Bacharach… - Clinical …, 2018 - Taylor & Francis
Purpose The aim of this study was to evaluate the safety and efficacy of OTX-101, a clear
nanomicellar aqueous solution of cyclosporine, in the treatment of dry eye disease (DED) …
nanomicellar aqueous solution of cyclosporine, in the treatment of dry eye disease (DED) …